Q1 2026 Insight Molecular Diagnostics Inc Earnings Call Transcript

May 13, 2026 / 09:00 PM GMT

Release Date Price: $5.1 (+2.41%)

Transcript 10-Q8-K

Key Points

Positve

Insight Molecular Diagnostics Inc (IMDX) has submitted Graftassure DX to the FDA and is experiencing high engagement, indicating progress in the review process.
The company is expanding its market presence with early orders from a Swiss transplant hospital and expected orders from Southeast Asia, demonstrating international interest.
The Galactic Registry study is gaining traction with 34 U.S. transplant centers expressing interest, up from 28 centers six weeks ago, showing strong engagement.
Insight Molecular Diagnostics Inc (IMDX) has achieved TUFSUD ISO 13,485 certification and is targeting regulatory compliance in the UK and EU, indicating a focus on international expansion.
The company is planning to expand its Graftassure technology into heart transplant testing, leveraging its organ-agnostic design, which could open new market opportunities.

Negative

The company's Q2 2026 revenue projection is modest at about a quarter million dollars, with a significant portion from laboratory services rather than product sales.
Projected cash burn for the second quarter is high at over $9 million, which is expected to be the peak for the year, indicating financial strain.
There is uncertainty in revenue predictions, which could impact cash burn and financial stability.
The company faces challenges in placing instruments in the field, which could delay the commercialization of Graftassure DX post-FDA clearance.
The European market's reimbursement landscape remains uncertain, which could affect the speed and volume of market penetration compared to the U.S.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMDX.OQ - Insight Molecular Diagnostics Inc
Q1 2026 Insight Molecular Diagnostics Inc Earnings Call
May 13, 2026 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Quarter 2026 results.

If you have not seen today's shareholder letter, please visit Insight Molecular Diagnostics Investors Relations page at investors.imdxinc.com.

Today's prepared remarks build upon the information already shared in this robust letter.

Joining us today are Insight Molecular Diagnostics President and CEO Josh Riggs. Chief Science Officer Eki Schutz, and CFO Andrea James.

We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions.

Before turning the call over to Josh Riggs, I'd like to go over our safe harbor.

The company will make projections and forward-looking statements regarding

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.